Garima Sharma MD, FACC, FAHA’s Post

Preeclampsia, a hypertensive disorder of pregnancy, occurs in 2–8% of pregnancies and is a leading contributor to significant fetal, neonatal, and maternal morbidity and mortality. Serious threats for the mother and fetus are associated with early onset preeclampsia, especially before 27 weeks gestation, which drives the need for early detection of preeclampsia, and timely intervention to achieve better outcomes. The Siemens Healthineers sFlt-1 and PlGF assays available on the Atellica® IM and ADVIA Centaur® Immunoassay Systems can be used to determine the PE ratio intended for use in the prognosis of preterm delivery and adverse outcomes in women presenting with signs and symptoms of preeclampsia. . . . For more details, click here: https://lnkd.in/dutHX2Mc #womenhealth #InternationalWomensDay #WomensDay #IWD2024

🌟 New Blog Alert! 🌟 📢 Excited to share our latest blog post: Addressing Obesity in Pregnancy 📝 Published: July 23, 2024 Obesity in pregnancy is a significant concern, posing risks to both mother and child increasing the risk of complications and long-term health risks. Key Points: -Over half of pregnant women in the USA are classified as obese. -Obesity increases the risk of gestational diabetes, pre-eclampsia, and other serious maternal health issues. -Traditional management strategies like medication and bariatric surgery are unsuitable during pregnancy. -Lifestyle interventions alone often fall short in preventing excessive weight gain. Mother Goose Health simplifies administrative demands on healthcare providers and engages expectant mothers with a comprehensive support system. Dive deeper into the systemic challenges and discover how Mother Goose Health is paving the way for better prenatal care! 🌼 🔗Read the full blog here: https://lnkd.in/gdMxS9US #MaternalHealth #PrenatalCare #ObesityInPregnancy #HealthcareInnovation #MotherGooseHealth #TransformingHealthcare #HealthTech

#Gestationaldiabetes, a disease that can lead to multiple pregnancy and delivery complications, is the most common pregnancy metabolic complication, affecting 1 in 7 pregnancies. Existing research has shown that excess insulin resistance in pregnancy contributes to gestational diabetes, but the exact causes of this resistance remain unclear. A new study led by Harvard Pilgrim Health Care Institute's Marie-France Hivert has highlighted a potential risk factor for the development of gestational diabetes: a deficit in placental insulin-like growth factor 1 (IGFB1), and low IGFBP1 circulating levels. Read the study in Nature Portfolio #NatureCommunications: https://lnkd.in/ekceUQtw

🔍 Unlocking the Potential of Aspirin: Insights into Optimizing Pregnancy Outcomes in ART-related Twins 🔍 This study delves into the nuanced relationship between #lowdoseaspirin (LDA) use and adverse outcomes in ART-related twin pregnancies, highlighting both its potential benefits and limitations. While the findings suggest a promising reduction in preeclampsia risk without significant bleeding concerns, the varying impacts on hypertensive disorders prompt reflection on underlying mechanisms and patient-specific factors. Moreover, the observed differences in outcomes based on maternal age raise intriguing questions about the interplay between aspirin efficacy and biological variables. Could age-related physiological variations influence aspirin's preventive effects differently? Exploring these nuances could offer deeper insights into tailoring interventions for improved maternal and neonatal outcomes. Kudos to Dr. Sushama R. Chaphalkar and the team for their thought-provoking research, paving the way for informed decision-making in clinical practice! 💡👩🔬 "https://lnkd.in/g2mZfAaJ" #MaternalHealth #NeonatalOutcomes #ResearchInsights #HealthcareAnalysis #ART #PregnancyComplications

Preeclampsia is a mortal enemy of pregnancy. It complicates 4% of pregnancies, and is responsible for 46,000 maternal deaths and 500,000 fetal deaths each year. 🎯 Lets start talking about implementing sFlt-1/PlGF in all pregnant women hospitalized with a hypertensive disorder aiming to identify EARLIER those who will develop severe preeclampsia. ✅ Join our FREE 𝗜𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝘃𝗲 𝗠𝗮𝘀𝘁𝗲𝗿𝗰𝗹𝗮𝘀𝘀 on 𝗣𝗿𝗲𝗲𝗰𝗹𝗮𝗺𝗽𝘀𝗶𝗮 to update data on prediction, prevention, diagnosis and management of complications. 📆 January 19th, 9:00-12:00 (BCN, GMT +1) 👇 Register now for free! https://lnkd.in/dhUwVddn 🔎 Extremely important data in the NEJM-PRAECIS study ► https://lnkd.in/dgj4fBNK

Greater risk of type 2 diabetes progression in multifetal gestations with gestational diabetes: the impact of obesity - Cox regression analysis for the prediction of T2DM Cumulative incidence of T2DM evaluated by Cox regression analysis in up to 5-year follow-up, stratified to 4 groups based on plurality and GDM diagnosis. The singleton pregnancy without GDM group was considered the reference group. https://ow.ly/cluZ50SR07z

Greater risk of type 2 diabetes progression in multifetal gestations with gestational diabetes: the impact of obesity - Cox regression analysis for the prediction of T2DM Cumulative incidence of T2DM evaluated by Cox regression analysis in up to 5-year follow-up, stratified to 4 groups based on plurality and GDM diagnosis. The singleton pregnancy without GDM group was considered the reference group. https://ow.ly/KLQI50T2S8W

May is Preeclampsia Awareness Month, a month-long communication campaign to raise awareness of this life-threatening hypertensive disorder of pregnancy. Our 2024 theme is "Predict Prevent Prevail." Researchers and clinicians still do not fully understand why preeclampsia and other hypertensive disorders occur in 5-8% of all pregnancies. Currently, we have few options besides a patient's medical and pregnancy history to help us predict what patients may be at risk for preeclampsia. Our only prevention tool is to place high-risk patients on prenatal aspirin, in the hopes that it may delay or prevent the onset of preeclampsia. But with more research and improved healthcare practices, we can prevail over preeclampsia. It will take us all: patients raising their voices in driving research and improving healthcare practices. Researchers receiving funding to investigate preeclampsia. Clinicians implementing what research shows saves lives. Policymakers prioritizing maternal health research funding in general and preeclampsia research in specific. Grab graphics at https://lnkd.in/g8FRWAMi and spread awareness all month long! #Preeclampsia #PreeclampsiaAwarenessMonth #PredictPreventPrevail #PreAM24

Maternal mortality is increasing in the U.S. A new FNIH Biomarkers Consortium partnership will address a leading cause—preeclampsia—by examining biomarkers that could predict a woman’s risk of developing the disorder early in pregnancy. Learn more: https://lnkd.in/eKfz7z5X #fnih #maternalhealth #womenshealth #biomarkers #preeclampsia #bridgestobreakthroughs

Hypertensive disorders of pregnancy (HDP) are a leading cause of maternal morbidity and mortality worldwide. With conditions like chronic hypertension, white-coat hypertension, and preeclampsia posing serious risks to both mother and baby, timely and accurate blood pressure (BP) management is critical. Recent studies in the Hypertension Research Journal highlights the importance of out-of-office BP monitoring, in predicting and managing these risks. Evidence shows that targeting stricter BP control can reduce the incidence of preeclampsia and improve pregnancy outcomes.   To read the full article clear here: https://lnkd.in/dYT6PbiM Biobeat's Cuff-less Blood Pressure Monitoring solution offers advanced 24-hour hypertension monitoring helping clinicians make more informed decisions in managing HDP. To learn more on Biobeat's offering click here: https://lnkd.in/d2-JVzus #MaternalHealth #HypertensiveDisorders #PregnancyCare #RemoteMonitoring #BloodPressureManagement #Biobeat #Hypertension